Sort
16,300 grants matching “fatty liver disease”
Nuclear receptors: action, functions, and roles in disease
$591,726Anton M Jetten · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
Fecal microbiota transplant for Alcohol-Associated Cirrhosis
$591,596Jasmohan S Bajaj · Virginia Commonwealth University · R01 · FY2024 · AA
Metabolic Reprogramming by Protease-activated Receptor 2
$591,270Athan Kuliopulos · Tufts Medical Center · R01 · FY2023 · DK
Altered Lipid Droplet Trafficking: Role in Alcoholic Fatty Liver Disease
$591,050Carol A Casey · University Of Nebraska Medical Center · R01 · FY2016 · AA
TMEM55B as a molecular determinant of NAFLD
$591,003Marisa Wong Medina · University Of California, San Francisco · R56 · FY2023 · DK
Elucidating the consequences of dietary sugar consumption on the gut microbiota
$590,990Guy Edmund Townsend · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2023 · DK
Role of IRF3 in Energy and Glucose Homeostasis
$590,987Evan D Rosen · Beth Israel Deaconess Medical Center · R01 · FY2023 · DK
Characterizing the Human Imprint Regulatory Regions Associated with Childhood Obesity
$590,971David Skaar · North Carolina State University Raleigh · R01 · FY2022 · HD
Insulin Resistance, Inflammation and Vascular Remodeling
$590,917Allison B Goldfine · Beth Israel Deaconess Medical Center · P50 · FY2012 · HL
Genetic and Metabolic Basis of Familial Lipodystrophies
$590,898Abhimanyu Garg · Ut Southwestern Medical Center · R01 · FY2010 · DK
Therapeutic Potential of FGF21 for Alzheimerâs Disease
$590,721Matthew Joseph Potthoff · University Of Iowa · R01 · FY2024 · AG
Therapeutic Potential of FGF21 for Alzheimerâs Disease
$590,721Matthew Joseph Potthoff · University Of Iowa · R01 · FY2023 · AG
The macro- and micro- anatomy and pathology of the aging kidney
$590,664Andrew D Rule · Mayo Clinic Rochester · R01 · FY2012 · DK
Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients
$590,183Jeremy Dahl · Stanford University · R01 · FY2020 · EB
Exosomes and insulin action in metabolically healthy and unhealthy obesity
$590,157Samuel Klein · Washington University · R01 · FY2024 · DK
Liver Cancer Risk with rAAV Gene Therapy
$590,097Markus Grompe · Oregon Health & Science University · R01 · FY2019 · CA
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy
$590,081Srinivasan Dasarathy · Cleveland Clinic Lerner Com-Cwru · U01 · FY2022 · DK
Unraveling the Complexity of Lipoprotein(a) Metabolism: Human Kinetic Studies
$589,918Gissette Reyes-Soffer · Columbia University Health Sciences · R01 · FY2021 · HL
Transgenerational obesity caused by ancestral exposure to obesogens in utero: changes in germline genomic architecture, roles of gonadal somatic cells, and metabolomic analysis of sexual dimorphism
$589,708Bruce Blumberg · University Of California-Irvine · R01 · FY2020 · ES
Physiology of Lipid Droplets and Triglyceride Storage
$589,475Robert V Farese · Harvard School Of Public Health · R01 · FY2015 · DK
Clinical utility of leptin therapy in syndromic forms of insulin resistance.
$589,467Rebecca Brown · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Molecular and Clinical Studies of Insulin Resistance
$589,467Rebecca Brown · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Genotype-Phenotype relationships underlying aerobic capacity and metabolic health
$589,426Jun Li · University Of Michigan At Ann Arbor · R01 · FY2014 · DK
Alterations in Post-Receptor Insulin Signaling in Diabetes and Insulin Resistance
$589,410C Ronald Kahn · Joslin Diabetes Center · R01 · FY2023 · DK
Lymphatics in the liver
$589,312Yasuko Iwakiri · Yale University · R01 · FY2023 · DK